Open AccessRisk of total and cardiovascular mortality, major cardiovascular events in patients with type 2 diabetes mellitus, depending on therapy choice upon making a diagnosis
Author(s) -
V.І. Pankiv,
L.A. Khutorska
Publication year - 2013
Publication title -
bukovinsʹkij medičnij vìsnik
Language(s) - English
Resource type - Journals
eISSN - 2413-0737
pISSN - 1684-7903
DOI - 10.24061/2413-0737.xvii.1.65.2013.20
Subject(s) - medicine , glimepiride , metformin , glibenclamide , diabetes mellitus , myocardial infarction , type 2 diabetes mellitus , type 2 diabetes , relative risk , risk factor , sulfonylurea , surgery , endocrinology , insulin , confidence interval
The purpose of this research is studying the risk of the total and cardiovascular mortality rate as well as the risk of the development of myocardial infarction (MI) and acute disturbances of the cerebral circulation (ADCC) in patients with type 2 diabetes mellitus (DM), depending on the choice of a peroral sugar-reducting agent (PSRA) after making a diagnosis. A retrospective cohort study was undertaken on the basis of operative lists of type 2 DM patients, being on a dispensary registration at medical treatment – preventive facilities of the Transcarpathian region. The patients with type 2 DM were subdivided into cohorts, depending on the type of obtained therapy: with metformin, glyclazide, glibenclamide and glimepiride. Higher risks of the total and cardiovascular mortality rate, the risk of the development of ADCC and the risk of death from ADCC as well as the risk of the development of MI as compared to the starting metformin treatment were detected in patients with type 2 DM who received sulfonylurea drugs as staring therapy in 5 years after establishing the diagnosis. A relative risk (RR) of ADCC was higher with glyclazide, glibenclamide and glimepiride compared with metformin, however, a RR of fatal ADCC is considerably higher only with glibenclamide and with glimepiride. A reliable decrease of the risk of fatal ADCC was marked with glyclazide compared to glibenclamide.